Professor, Neurology and Rehabilitation, University of Cincinnati College of Medicine
Neurology
Doctor Alok Sahay, MD is an expert in the field of Neurology. He went to University Hospital - University of Cincinnati College of Medicine. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Doctor Alok Sahay, MD is also a published physician. He has 43 publication published. The most recent publication is: Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study: Effects on Nonmotor Symptoms and Tolerability. Alok Sahay accepts Medicare payments and is listed with Medicare.gov.
Publications
- Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study: Effects on Nonmotor Symptoms and Tolerability.
- Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's Disease.
- Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's Disease.
- Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit.
- Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's Disease.
- A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical Dystonia.
- Phase II safety, tolerability, and dose selection study of isradipine as a potential Disease-modifying intervention in early Parkinson's Disease (STEADY-PD).
- Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
- Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.
- Meta-analysis of Parkinson's Disease: identification of a novel locus, RIT2.
- Serum urate and probability of dopaminergic deficit in early "Parkinson's Disease".
- The modified bradykinesia rating scale for Parkinson's Disease: reliability and comparison with kinematic measures.
- Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's Disease.
- Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical Dystonia.
- Copy number variation in familial Parkinson Disease.
- Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's Disease: unfavorable risk-benefit ratio.
- Predictors of time to requiring dopaminergic treatment in 2 Parkinson''s Disease cohorts.
- Twice-daily, low-dose pramipexole in early Parkinson's Disease: a randomized, placebo-controlled trial.
- Cancer incidence in a trial of an antiapoptotic agent for Parkinson's Disease.
- Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson''s Disease.
- Maternal inheritance and mitochondrial DNA variants in familial Parkinson's Disease.
- A comparison of treatment thresholds in two large Parkinson's Disease clinical trial cohorts.
- Genomewide association study for onset age in Parkinson Disease.
- A double-blind, delayed-start trial of rasagiline in Parkinson's Disease.
- Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.
- Alpha-synuclein and familial Parkinson's Disease.
- Variation in GIGYF2 is not associated with Parkinson Disease.
- Mutations in GBA are associated with familial Parkinson Disease susceptibility and age at onset.
- Genomewide association study for susceptibility genes contributing to familial Parkinson Disease.
- Clinical correlates of depressive symptoms in familial Parkinson's Disease.
- Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson Disease.
- Serum urate as a predictor of clinical and radiographic progression in Parkinson Disease.
- LRRK2 mutation analysis in Parkinson Disease families with evidence of linkage to PARK8.
- Sarizotan as a treatment for dyskinesias in Parkinson's Disease: a double-blind placebo-controlled trial.
- R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's Disease mutation.
- Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's Disease.
- Mutations in DJ-1 are rare in familial Parkinson Disease.
- Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's Disease.
- A randomized controlled trial of etilevodopa in patients with Parkinson Disease who have motor fluctuations.
- Deterministic center of pressure patterns characterize postural instability in Parkinson's Disease.
- Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1.
Schools
Sawai Man Singh Medical College Rajasthan University
University Hospital
Procedures Preformed
- EEG (Electroencephalogram)
- Non-Cosmetic Chemodenervation
Conditions Treated
- Alzheimer's Disease
- Anterior Horn Disease
- Ataxia
- Autonomic Disorders
- View All
Doctors Specialties
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Oregon Health & Science University
-
University Hospital - University of Cincinnati College of Medicine
-
Sawai Man Singh Medical College
Hospital
-
University of Cincinnati Medical Center
Drug Facts
| NPI NUMBER |
|
1730115684 |
| NPPES Provider LastName |
|
SAHAY |
| NPPES Provider FirstName |
|
ALOK |
| NPPES Provider ZIPCode |
|
45219 |
| NPPES Provider State |
|
OH |
| Specialty Description |
|
Neurology |
| Total Claim Count |
|
1513.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1730115684 |
| Last Name Of The Provider |
SAHAY |
| First Name Of The Provider |
ALOK |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.